This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Celsion Short Thesis, Hemispherx

BOSTON ( TheStreet) -- The second-to-last Biotech Stock Mailbag of 2012 begins with an email from Simon K.

" Celsion (CLSN - Get Report) has been a great run-up stock lately, but do you think this momentum will last into next year?" he asks.

Celsion is a fantastic and profitable example of the "biotech run-up" strategy espoused by traders, including TheStreet contributor Mark Messier, who runs a subscription trading service built around profiting from biotech stocks that run up in value ahead of catalysts like clinical-trial results and FDA drug-approval decisions.

Messier nailed the trading opportunity in Celsion, with shares up 63% since this Nov. 14 column.

If the surge in Celsion's value is attributable to traders' run-up into the Thermodox phase III trial results in January, remember to heed the rest of Messier's advice: Take profits before the event. If Thermodox blows up, you don't want to kick yourself for not reducing risk exposure and banking easy returns.

Messier on Celsion:

Cautious run-up traders should exit positions before the end of the year to avoid being caught long when the Thermodox results are announced. If you're thinking about holding a position through the results, I recommend taking profits on your initial trade and keeping "free shares" only. Those who like to trade using options can roll run-up profits into calls that expire after data are expected. Because we don't know exactly when in January Celsion will release Thermodox data, it's safest to use your profits to buy calls that expire in February 2013.

Investors get intoxicated on explosive stock runs like we're seeing with Celsion, making it easy to forget the significant risks attached to the Thermodox clinical trial. So let's sober up a bit with a few words from a Celsion short.

I spoke this week with one of my favorite fund managers who focuses almost exclusively on biotech shorts. He is prohibited by his fund's rules from using his name in print. Most recently, he scolded me for being bullish about Clovis Oncology's (CLVS) pancreatic cancer drug CO-101. He was short and right. He was also very early and right about Elan's Alzheimer's drug bapineuzumab. This guy isn't always right, but he always brings a well-researched perspective to support this bearish views.

Before I get into the reasons he believes the Thermodox phase III study in liver cancer will fail, let's go over some background on the therapy.

Thermodox consists of tiny, heat-sensitive spheres of fat that contain a payload of the chemotherapy drug doxorubicin. When injected into the body, Thermodox accumulates at the site of the tumors. When the tumor site is heated to about 107 degrees using radio waves (radiofrequency thermal ablation, or RFA), the Thermodox spheres melt, bathing the tumor and adjacent tissue in high levels of doxorubicin.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
CLSN $2.50 -5.30%
HEB $0.27 2.31%
AAPL $125.80 -2.25%
FB $77.56 -1.59%
GOOG $530.80 -1.85%

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs